Redeye Headquarters - special invitation required
English language
Welcome to a lunch presentation with Ultimovacs and CEO Carlos de Sousa and Chief Innovation Officer Sara Mangsbo
The company will provide an update on its clinical programme and specifically the expectations and potential impact from the upcoming readout in the INITIUM study in March. UV1 is the first off-the-shelf cancer vaccine investigated in a randomized trial in advanced melanoma, the most serious form of skin cancer.
The company’s presentation, held in English, is followed by a question and answer session.
Special invitation required.
NOTE
Companies and schedules may change before the event starts. Save the date to your calendar by using Add to calendar.